We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-1.41%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.59B
AUM Growth
-$205M
Cap. Flow
-$105M
Cap. Flow %
-4.06%
Top 10 Hldgs %
43.13%
Holding
169
New
17
Increased
28
Reduced
45
Closed
8

Top Buys

Rank Stock Value
1
AMGN icon
Amgen
AMGN
+$42.8M
2
ABBV icon
AbbVie
ABBV
+$22.8M
3
BMY icon
Bristol-Myers Squibb
BMY
+$21.8M
4
CELG
Celgene Corp
CELG
+$14.3M
5
NVO
Novo Nordisk
NVO
+$10.1M

Top Sells

Rank Stock Value
1
ABT icon
Abbott
ABT
+$25.1M
2
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$24.3M
3
AGN
Allergan plc
AGN
+$23.5M
4
GILD icon
Gilead Sciences
GILD
+$21.3M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$16.2M

Sector Composition

Rank Sector Weight
1 Healthcare 92.75%
2 Real Estate 2.87%
3 Financials 0.33%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GWPH
101
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$3.3M 0.13%
+25,000
New +$2.94M
TRIL
102
DELISTED
Trillium Therapeutics Inc.
TRIL
$3.29M 0.13%
450,000
-50,000
-10% -$414K
VRNA
103
DELISTED
Verona Pharma
VRNA
$3.28M 0.13%
275,000
– –
PRGO icon
104
Perrigo
PRGO
$1.43B
$3.25M 0.13%
37,300
– –
DXCM icon
105
DexCom
DXCM
$28.8B
$3.1M 0.12%
215,800
-215,800
-50% -$2.81M
RARX
106
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$3.03M 0.12%
356,237
-39,581
-10% -$487K
ARGX icon
107
argenx
ARGX
$54.6B
$2.93M 0.11%
46,466
-28,534
-38% -$934K
AGN.PRA
108
DELISTED
Allergan plc
AGN.PRA
$2.93M 0.11%
5,000
– –
CYTK icon
109
Cytokinetics
CYTK
$10.9B
$2.85M 0.11%
+350,300
New +$3.98M
LXRX icon
110
Lexicon Pharmaceuticals
LXRX
$1.04B
$2.75M 0.11%
+278,700
New +$2.9M
CASC
111
DELISTED
Cascadian Therapeutics, Inc.
CASC
$2.74M 0.11%
740,769
+286,869
+63% +$1.17M
PHG icon
112
Philips
PHG
$25.8B
$2.65M 0.1%
+92,219
New +$2.78M
ADVM
113
DELISTED
Adverum Biotechnologies
ADVM
$2.6M 0.1%
74,397
+44,389
+148% +$1.46M
ONC
114
BeOne Medicines Ltd
ONC
$33.4B
$2.56M 0.1%
+26,170
New +$2.4M
TXMD icon
115
TherapeuticsMD
TXMD
$23.5M
$2.54M 0.1%
+8,400
New +$2.34M
THC icon
116
Tenet Healthcare
THC
$21.8B
$2.49M 0.1%
164,500
– –
UTHR icon
117
United Therapeutics
UTHR
$26.2B
$2.4M 0.09%
16,220
-27,741
-63% -$3.53M
HZNP
118
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$2.38M 0.09%
162,900
– –
BCRX icon
119
BioCryst Pharmaceuticals
BCRX
$2.35B
$2.21M 0.09%
449,255
+126,000
+39% +$610K
ACIU icon
120
AC Immune
ACIU
$241M
$2.2M 0.08%
171,813
+130,894
+320% +$1.54M
HSIC icon
121
Henry Schein
HSIC
$9.7B
$2.19M 0.08%
40,035
-40,035
-50% -$2.32M
HR
122
DELISTED
Healthcare Realty Trust Incorporated
HR
$2.18M 0.08%
68,000
– –
IPXL
123
DELISTED
Impax Laboratories, Inc.
IPXL
$2.07M 0.08%
124,335
– –
ONCE
124
DELISTED
Spark Therapeutics, Inc. Common Stock
ONCE
$1.99M 0.08%
38,706
+14,406
+59% +$1.03M
CDTX
125
DELISTED
Cidara Therapeutics
CDTX
$1.95M 0.08%
14,324
– –
3 4
5
6 7

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q4 2017 Portfolio in Review

As of Q4 2017, Tekla Capital Management held 169 positions worth $2.59B, down 7.3% from $2.8B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Tekla Capital Management withdrew a net $105M in Q4 2017, closing 8 positions and reducing 45 holdings. Its most notable exit was Intercept Pharmaceuticals, Inc., an estimated $7.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 93% a quarter earlier, followed by Real Estate and Financials.

Against the trend, Tekla Capital Management opened a new position in Bristol-Myers Squibb worth $21.4M.

  • Tekla Capital Management's largest Q4 2017 buy was Bristol-Myers Squibb: 349,121 shares worth $21.4M.
  • Tekla Capital Management added most to Amgen in Q4 2017, an estimated $42.8M increase.
  • Tekla Capital Management's biggest Q4 2017 reduction was Abbott, cutting an estimated $25.1M.
  • Tekla Capital Management fully exited Intercept Pharmaceuticals, Inc. in Q4 2017, selling an estimated $7.15M.
  • Tekla Capital Management's ten largest holdings make up 43% of its $2.59B portfolio in Q4 2017.
  • Tekla Capital Management opened 17 new positions and closed 8 in Q4 2017.
  • Tekla Capital Management's portfolio value fell 7.3% quarter-over-quarter to $2.59B.

Based on Tekla Capital Management's 13F filing for Q4 2017, filed 14 Feb 2018.